RTK Group is a family office backed biopharmaceutical advisory and investment fund focused on emerging technologies having disruptive impact and significant potential to benefit patients.
We focus our efforts where we can leverage our unique expertise in company formation and technology development to assist high‐performing management teams realize the full value potential of their technology.
Committed to Making Game-Changing Healthcare Contributions
Team of experienced life‐science professionals with experience across all sectors of health care
Long-Term Investor With Innovative Solutions
Improving the World – One Investment at a Time
We embrace scientific risk and support research with high impact potential. Our belief is that investing in promising concepts backed by solid science creates the potential for significant value creation.
High performing teams are critical to allow promising technologies to realize their full potential. We back innovators at all stages of their entrepreneurial career and support teams as needed with our expertise in company formation and technology development.
Our ultimate goal is to improve the human condition through our support of technology development. Leaving the potential for a better future for our future generations is what motivates us to foster scientific innovation and teams dedicated to improving patient lives.
Founding Partner
Dr. Kohli founded RTK Group in December 2019. Dr. Kohli has served as an Attending Physician and Assistant Professor with the Tufts University School of Medicine for nearly 20 years in the Department of Medicine, Division of Geographic Medicine and Infectious Diseases, with clinical focus areas of transplant medicine, HIV infection and insulin resistance.
In addition to her career in academic medicine, Dr. Kohli has been extensively involved in academic and commercial research, being awarded a NIH K23 award early in her scientific career and receiving a developmental award from the Center for AIDS Research, generating numerous publications and invited presentations. Dr. Kohli has assisted numerous companies across all aspects of development and strategy, including serving as the lead investigator on several pivotal clinical studies, consultant on clinical development strategy, and market analysis.
Dr. Kohli completed her residency in Internal Medicine at the Beth Israel Deaconess Medical Center and fellowship in Infectious Disease at the Albert Einstein College of Medicine. Dr. Kohli received her MD from the University of Rochester School of Medicine and Dentistry, and a BS in Biological Sciences from Cornell University. Dr. Kohli was recently recognized as a Castle Connolly 2022 Top Doctor for her clinical practice excellence.
Managing Director, RTK Group
Dr. Muni has been a Managing Director of RTK Group since December 2019. Prior to joining RTK Group, Dr. Muni served for over 20 years in senior roles across the entire life sciences value chain, most recently serving as the CEO of Azurity Pharmaceuticals. In his role, Dr. Muni led two successful private equity transactions, including a company recapitalization and eventual successful company sale and exit. During his tenure, Dr. Muni led the transformation of the company from a virtually operated pharmacy distributor into a fully integrated specialty pharma, leading the acquisition of Silvergate Pharmaceuticals as well as overseeing the FDA approval and launch of two pipeline drugs, FIRVANQ® for clostridium dificile colitis and Katerzia® for pediatric hypertension.
Prior to CutisPharma, Dr. Muni served as the Head of New Product Planning and Corporate Strategy at Sunovion Pharmaceuticals, leading portfolio strategy and supporting corporate M&A and licensing. Prior to that, Dr. Muni was an engagement manager at the healthcare investment bank SVB Leerink. Prior to Leerink, he was a Medical Officer in the Division of Cardiovascular Devices at the FDA, serving as the lead medical reviewer for drug-eluting intracoronary stents.
Over the past 20 years, Dr. Muni has maintained staff appointments at Harvard Medical School and its teaching hospitals, including Brigham and Women’s Hospital, Dana Farber Cancer Institute, and Faulkner Hospital. Dr. Muni is currently appointed as a Visiting Scholar at Harvard University’s Wyss Institute, mentoring project teams and collaborating on technology development, partnering, and company formation.
Dr. Muni completed his residency in Internal Medicine at the Brigham and is appointed as Associate Physician on the hospitalist service, supervising medical residents and students. Dr. Muni received his MD as well as Master of Science in Public Health (biostatistics) from the Tulane University School of Medicine, and a BA in Business Economics and B.Sc. in Biochemistry from Brown University
RTK is a biopharmaceutical advisory and investment fund that supports companies
by enabling them to develop promising technologies and reach their potential to benefit patients.
We have one goal: to enable better patient lives and a better world through better healthcare. We take great satisfaction in partnering with companies having high potential to disrupt the healthcare ecosystem and helping support high‐performing management teams to realize their goals.